Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Virginia Ashley

Psychiatry Towson, MD Medical Doctor

NPI 1396895561 CMS profile 108300

7600 Osler Dr, Ste 304, Towson, MD 21204

Open in the dashboard

General payments

$1,409

64 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Virginia Ashley of Towson, MD is reported in the CMS Open Payments database as having received $1,409 across 64 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $126 5
2024 General $343 10
2023 General $97 4
2022 General $181 7
2021 General $174 8
2020 General $98 6
2019 General $391 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Virginia Ashley
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Virginia Ashley were reported at $126. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Virginia Ashley Psychiatry median Middle half National median
2019 $391 $184 $59–$605 $163
2020 $98 $119 $36–$372 $114
2021 $174 $143 $43–$576 $132
2022 $181 $153 $50–$590 $149
2023 $97 $170 $56–$651 $160
2024 $343 $179 $57–$673 $164
2025 $126 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lundbeck LLC $629 26 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $258 10 payments
  3. Allergan Inc. $174 16 payments
  4. Otsuka America Pharmaceutical, Inc. $149 2 payments
  5. AbbVie, Inc. $109 6 payments
  6. Shire North American Group Inc $67 3 payments
  7. Sunovion Pharmaceuticals Inc. $23 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,409 64 payments
Products named General payments · program years 2019–2025
  1. REXULTI Psychiatry $629 26 payments
  2. VRAYLAR Neuroscience $174 16 payments
  3. TRINTELLIX Neuroscience $170 6 payments
  4. ABILIFY MAINTENA $125 1 payment
  5. VRAYLAR Neuroscience $109 6 payments
  6. Trintellix Central Nervous System (CNS) $87 4 payments
  7. VYVANSE $67 3 payments
  8. REXULTI Psychiatry $24 1 payment
  9. LATUDA $23 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

936

Median for Psychiatry: 574

Drug cost

$63,851

Median for Psychiatry: $27,624

Branded share of claims

20.9%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 13 $18,055
Lurasidone Hcl Generic 17 $17,603
Aripiprazole Generic 24 $4,190
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 20 $2,907
Clozapine Generic 14 $2,509
Bupropion Xl Bupropion Hcl Brand 57 $2,431
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 23 $1,845
Methylphenidate Hcl Generic 52 $1,602
Escitalopram Oxalate Generic 59 $1,417
Oxazepam Generic 12 $1,353

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$193,532

Medicare's payments for the services billed

Medicare patients

77

Average age 72

Services billed

1,955

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
High blood pressure 60%
Arthritis 49%
Osteoporosis 27%
Diabetes 22%
Ischemic heart disease 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Lundbeck LLC $170
$170 — —
ABILIFY MAINTENA
  • Otsuka America Pharmaceutical, Inc. $125
$125 — —
VRAYLAR
  • AbbVie, Inc. $48
$48 13 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

64 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record